Yamada T - Search Results

1

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.

Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Katayama Y, et al. Among authors: yamada t. Cancer Med. 2022 Feb;11(4):944-955. doi: 10.1002/cam4.4504. Epub 2022 Jan 14. Cancer Med. 2022. PMID: 35029047 Free PMC article.

2

Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.

Iwasaki Y, Ohsugi S, Natsuhara A, Tsubokura T, Harada H, Ueda M, Arimoto T, Hara H, Yamada T, Takesako T, Kohno K, Hosogi S, Nakanishi M, Marunaka Y, Nishimura T. Iwasaki Y, et al. Among authors: yamada t. Cancer Chemother Pharmacol. 2006 Dec;58(6):735-41. doi: 10.1007/s00280-006-0220-y. Epub 2006 Mar 25. Cancer Chemother Pharmacol. 2006. PMID: 16565832 Clinical Trial.

3

Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.

Ogino H, Yano S, Kakiuchi S, Yamada T, Ikuta K, Nakataki E, Goto H, Hanibuchi M, Nishioka Y, Ryan A, Sone S. Ogino H, et al. Among authors: yamada t. Cancer Lett. 2008 Jun 28;265(1):55-66. doi: 10.1016/j.canlet.2008.02.018. Epub 2008 Mar 24. Cancer Lett. 2008. PMID: 18364248

4

Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2.

Yamada T, Yano S, Ogino H, Ikuta K, Kakiuchi S, Hanibuchi M, Kanematsu T, Taniguchi T, Sekido Y, Sone S. Yamada T, et al. Cancer Sci. 2008 Aug;99(8):1603-10. doi: 10.1111/j.1349-7006.2008.00848.x. Cancer Sci. 2008. PMID: 18754873 Free article.

5

Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.

Yamada T, Muguruma H, Yano S, Ikuta K, Ogino H, Kakiuchi S, Hanibuchi M, Uehara H, Nishioka Y, Sone S. Yamada T, et al. Mol Cancer Ther. 2009 Jan;8(1):119-26. doi: 10.1158/1535-7163.MCT-08-0874. Mol Cancer Ther. 2009. PMID: 19139120 Free article.

6

Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.

Ohtsubo K, Watanabe H, Yamada T, Tsuchiyama T, Mouri H, Yamashita K, Yasumoto K, Ikeda H, Nakanuma Y, Yano S. Ohtsubo K, et al. Among authors: yamada t. Intern Med. 2009;48(18):1651-6. doi: 10.2169/internalmedicine.48.2432. Epub 2009 Sep 15. Intern Med. 2009. PMID: 19755768 Free article.

7

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S. Wang W, et al. Among authors: yamada t. Clin Cancer Res. 2009 Nov 1;15(21):6630-8. doi: 10.1158/1078-0432.CCR-09-1001. Epub 2009 Oct 20. Clin Cancer Res. 2009. PMID: 19843665

8

Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.

Yamada T, Ohtsubo K, Mouri H, Yamashita K, Yasumoto K, Izumi K, Zen Y, Watanabe H, Yano S. Yamada T, et al. Int J Clin Oncol. 2009 Oct;14(5):468-72. doi: 10.1007/s10147-008-0869-9. Epub 2009 Oct 25. Int J Clin Oncol. 2009. PMID: 19856060

9

E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.

Ikuta K, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, Uehara H, Sekido Y, Uenaka T, Nishioka Y, Sone S. Ikuta K, et al. Among authors: yamada t. Clin Cancer Res. 2009 Dec 1;15(23):7229-37. doi: 10.1158/1078-0432.CCR-09-1980. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934291

10

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Yamada T, et al. Clin Cancer Res. 2010 Jan 1;16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204. Epub 2009 Dec 15. Clin Cancer Res. 2010. PMID: 20008840

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,002 results

Search Page